SCHEMBL4536273

SCHEMBL4536273

Cc1cc(S(=O)(=O)N2CCC3(CC2)CN(C2CC2)C(=O)CO3)ccc1Br

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FASN P49327 5/20 0.57
ABL1 P00519 1/20 0.42
RIN1 Q13671 1/20 0.42
ALDH1A1 P00352 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
THRB P10828 1/20 0.39
NEK2 P51955 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
PKM P14618 1/20 0.37
MAPK1 P28482 1/20 0.36
TSHR P16473 1/20 0.36
POLB P06746 2/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4536297 0.89 FASN (0.58) FASNALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4539996 0.88 FASN (0.57) FASNALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4533515 0.87 FASN (0.55) FASNALDH1A1L3MBTL1LMNASMN1; SMN2
SCHEMBL4534422 0.85 FASN (0.55) FASNALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4536313 0.85 FASN (0.63) FASNALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4533528 0.84 FASN (0.50) FASNALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4542291 0.83 FASN (0.51) FASNALDH1A1KMT2ALMNASMN1; SMN2
SCHEMBL4537666 0.82 FASN (0.49) FASNALDH1A1LMNATP53MAPT
SCHEMBL4536955 0.81 FASN (0.58) FASNALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4540317 0.81 FASN (0.61) FASNALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2637660-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2013-09-18 EP disclosed
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC 2013-09-12 US disclosed
WO-2012064642-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237535-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 FASN 1/4885ABL1 2939/4885RIN1 3144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.